Glenmark Pharmaceuticals has launched a triple-drug FDC of Teneligliptin, Dapagliflozin, and Metformin in India for Type 2 Diabetes in Adults with Co-morbidities under the brand name Zita DM, aiming to improve glycemic control and lower the daily cost of therapy by 30%.